Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Heart Journal - Cardiovascular Pharmacotherapy Année : 2022

Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial

(1) , (1) , (1) , (1) , (2) , (3) , (3) , (3) , (1) , (4) , (5) , (6) , (1) , (1) , (7) , (8) , (9) , , (10) , (11) , (12) , (13) , (14) , (15) , (16) , (16) , (17) , (17) , (18) , (19) , (20) , (20) , (21) , (22) , (23) , (24) , (25) , (25) , (26) , (27) , (27) , (28) , (29) , (30) , , , (31) , (32, 33) , (34) , (35) , (36) , (1) , (1) , (1) , (1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
John Eikelboom
  • Fonction : Auteur correspondant
  • PersonId : 1135021

Connectez-vous pour contacter l'auteur
Alexander Parkhomenko
  • Fonction : Auteur
Deepak Bhatt
Yan Liang
  • Fonction : Auteur
Jun Zhu
  • Fonction : Auteur
Christian Torp-Pedersen
Aldo Maggioni
Peter Verhamme
Khairul Ibrahim
  • Fonction : Auteur
Basil Lewis
  • Fonction : Auteur

Résumé

Abstract Aims To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) randomized trial who were treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily during long term open label extension (LTOLE). Methods and results Of 27 395 patients enrolled in COMPASS, 12 964 (mean age at baseline 67.2 years) from 455 sites in 32 countries were enrolled in LTOLE and treated with the combination of rivaroxaban and aspirin for a median of 374 additional days (range 1–1 191 days). During LTOLE, the incident events per 100 patient years were: for the primary outcome (cardiovascular [CV] death, stroke, or myocardial infarction [MI]) 2.35 (95% CI 2.11–2.61), mortality 1.87 (1.65–2.10), stroke 0.62 (0.50–0.76) and MI 1.02 (0.86–1.19), with confidence intervals that overlapped those seen during the randomized treatment phase with the combination of rivaroxaban and aspirin. The incidence rates for major bleeding were 1.01 (0.86–1.19) and for minor bleeding 2.49 (2.24–2.75), compared with 1.67 (1.48–1.87) and 5.11 (95% CI 4.77–5.47), respectively, during the randomized treatment phase with the combination. Conclusion In patients with chronic CAD and/or PAD, extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals.
Fichier non déposé

Dates et versions

hal-03676188 , version 1 (23-05-2022)

Identifiants

Citer

John Eikelboom, Jacqueline Bosch, Stuart Connolly, Jessica Tyrwitt, Keith Fox, et al.. Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, ⟨10.1093/ehjcvp/pvac023⟩. ⟨hal-03676188⟩
11 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More